Neurocrine Biosciences Q3 Revenue Rises 41% to $1.12 Billion
Neurocrine reported third-quarter 2026 GAAP net income of $206.5 million and non-GAAP diluted EPS of $3.29. It raised 2026 INGREZZA net sales guidance to $2.90 billion–$2.925 billion.
Story updates
09:22:36 PM UTC
SquawkNews
Neurocrine Biosciences reported third-quarter 2026 revenue of $1.12B, up 41.2% from the prior-year quarter, while net income was $206.5M and diluted EPS was $1.96, both lower year over year. Growth reflected CRENESSITY and INGREZZA sales and contributions from VYKAT XR following the Soleno acquisit…
09:29:53 PM UTC
SquawkNews
Neurocrine: lucro líquido recua para 207 milhões de dólares no terceiro trimestre de 2026; receita s
09:40:22 PM UTC
SquawkNews
NEUROCRINE BIOSCIENCES - INGREZZA Q3 2026 NET PRODUCT SALES $801 MLN, UP 17% YEAR-OVER-YEAR - SEC FI
Neurocrine Biosciences reported third-quarter 2026 revenue of $1.12 billion, up 41% year over year. GAAP net income was $206.5 million, while non-GAAP diluted earnings per share reached $3.29. The company raised its 2026 INGREZZA net sales guidance to $2.90 billion—$2.925 billion.Financial Highligh…